COL18A1 and hereditary angioedema: Safety outcomes of the use of icatibant in HAE‐nC1 INH patients are consistent with the established safety profile of icatibant in patients with HAE with C1 INH deficiency 19, 20 and previous reports of safety in patients with HAE‐nC1 INH 17, 21, 22.